Current Environment: Production

Medical Services

Specialties

Programs & Services

Languages

  • English

Education

Undergraduate School

Rensselaer Polytechnic Institute

Troy, NY

Medical School

University of Massachusetts Medical School

Worcester, MA

Residency

Boston Combined Residency Program

Boston, MA

Fellowship

Boston Children's Hospital

Boston, MA

Fellowship

Advanced Inflammatory Bowel Disease Fellowship

Boston Children's Hospital

Boston, MA

Certifications

  • American Board of Pediatrics (Gastroenterology)
  • American Board of Pediatrics (General)

Professional History

Dr. Collen’s clinical and research interests lie in the care of patients with inflammatory bowel disease (IBD), including Crohn’s disease and ulcerative colitis. She has special interest in understanding and treating patients with very early onset IBD (VEOIBD), defined as disease onset at less than 6 years of age, and those with disease that has been refractory to conventional therapies. Dr. Collen completed an Advanced Fellowship in Pediatric Inflammatory Bowel Disease at Boston Children’s Hospital and is a recipient of a Crohn’s and Colitis Foundation Research Fellows Award. Her research interests are in understanding the underlying pathways that drive disease in her IBD patients with the ultimate goal of advancing options for personalized medicine.

Publications

  1. Discordance between a deep learning model and clinical-grade variant pathogenicity classification in a rare disease cohort. NPJ Genom Med. 2025 Feb 28; 10(1):17. View Abstract

  2. A progranulin variant causing childhood interstitial lung disease responsive to anti-TNF-a biologic therapy. Med. 2025 Feb 25; 100607. View Abstract

  3. Effectiveness and Safety of Adalimumab in Patients With Very Early-Onset Inflammatory Bowel Disease: A Retrospective Study on Behalf of the Porto Inflammatory Bowel Disease Working Group of European Society for Pediatric Gastroenterology Hepatology and Nutrition. Inflamm Bowel Dis. 2025 Jan 15. View Abstract

  4. Efficacy and Safety of Anti-Tumor Necrosis Factor Alpha in Very Early Onset Inflammatory Bowel Disease. Inflamm Bowel Dis. 2024 09 03; 30(9):1443-1453. View Abstract

  5. Breaking Down Barriers: Epithelial Contributors to Monogenic IBD Pathogenesis. Inflamm Bowel Dis. 2024 07 03; 30(7):1189-1206. View Abstract

  6. Discordance between a deep learning model and clinical-grade variant pathogenicity classification in a rare disease cohort. medRxiv. 2024 May 23. View Abstract

  7. Response to Letter to the Editor: "Failure Rate of Antitumor Necrosis Factor Alpha Biologics in Very Early Onset Inflammatory Bowel Disease". Inflamm Bowel Dis. 2024 03 01; 30(3):513-514. View Abstract

  8. Catalyzing change: Implementing standardised reporting in monogenic inflammatory bowel disease research. J Pediatr Gastroenterol Nutr. 2024 Apr; 78(4):759-762. View Abstract

  9. Clinical Remission of Severe Crohn's Disease with Empagliflozin Monotherapy in a Pediatric Patient with Glycogen Storage Disease Type 1b. JPGN Rep. 2023 Nov; 4(4):e356. View Abstract

  10. Rapid Clinical Remission With Upadacitinib in a Pediatric Patient With Refractory Crohn's Disease. Inflamm Bowel Dis. 2023 07 05; 29(7):1175-1176. View Abstract

  11. Pancreatitis-Associated Medication Use in Hospitalized Pediatric and Young Adult Patients With Acute Pancreatitis. J Pediatr Gastroenterol Nutr. 2023 08 01; 77(2):260-266. View Abstract

  12. Vertebral Compression Fractures in Very Early Onset Inflammatory Bowel Disease. JPGN Rep. 2023 Feb; 4(1):e283. View Abstract

  13. Clinical Phenotypes and Outcomes in Monogenic Versus Non-monogenic Very Early Onset Inflammatory Bowel Disease. J Crohns Colitis. 2022 Sep 08; 16(9):1380-1396. View Abstract

  14. Inflammatory Bowel Disease and Cardiovascular Diseases. Am J Med. 2022 12; 135(12):1453-1460. View Abstract

  15. Cytotoxic T Lymphocyte Antigen 4 Haploinsufficiency Presenting As Refractory Celiac-Like Disease: Case Report. Front Immunol. 2022; 13:894648. View Abstract

  16. An occurrence of apnea, bradycardia, and desaturation events resulting in a delay of discharge in late preterm and full term infants. Pediatr Neonatol. 2018 12; 59(6):630-631. View Abstract

  17. Economics of Home Monitoring for Apnea in Late Preterm Infants. Respir Care. 2017 Jan; 62(1):42-48. View Abstract

  18. Diagnostic Evaluation and Home Monitor Use in Late Preterm to Term Infants With Apnea, Bradycardia, and Desaturations. Clin Pediatr (Phila). 2016 Nov; 55(13):1210-1218. View Abstract

  19. The nondietary determinants of vitamin D status in pediatric inflammatory bowel disease. Nutrition. 2015 Jul-Aug; 31(7-8):994-9. View Abstract

  20. The vitamin D status in inflammatory bowel disease. PLoS One. 2014; 9(7):e101583. View Abstract

  21. Continuous feedings of fortified human milk lead to nutrient losses of fat, calcium and phosphorous. Nutrients. 2010 03; 2(3):230-40. View Abstract

Every patient with IBD has a unique experience of their disease and responses to therapy. Dr. Collen’s philosophy is to take the time to understand her patients’ experiences before making treatment recommendations that take into account her patients’ symptoms and goals.

BESbswy